[ad_1]
The International Organization for Migration selects the most advanced test to detect latent TB infections
QIAGEN NV (NYSE: QGEN) announced today that QuantiFERON-TB® Gold Plus (QFT- Plus), the gold standard for accurate and cost-effective testing of latent TB infections, has been approved by the International Organization for Migration (IOM) for the screening of migrants for TB infections.
As the United Nations agency for migration, IOM coordinates comprehensive medical care for some 20 million migrants, refugees and asylum seekers around the world. The IOM tender calls for QFT-Plus to be deployed in 16 countries in Africa, Asia and the Middle East during the Global Plan to end TB 2016-2020 Health is affected by TB.
QIAGEN works with governments and international institutions, non-governmental organizations and business partners to fight the global TB epidemic. More and more experts around the world recognize that accurate TB control requires accurate, laboratory-based screening for latent TB infections that can progress to active infectious TB. In 2018, the World Health Organization (WHO) and the United States Centers for Disease Control (CDC) have already approved interferon-gamma release badays (IGRAs) such as QFT-Plus. fourth-generation QIAGEN and third-generation QuantiFERON-TB® Gold (QFT) for latent TB screenings. The International Panel Physicians Association (IPPA) also explicitly supported QFT-Plus.
Click here for the full press release
Watch the original version on businesswire.com: https://www.businesswire.com/news/home/20180730005549/DE/
Relations with investors John Gilardi +49 2103 29 11711 or Dr. Ing. Sarah Fakih +49 2103 29 11457 e-mail: [email protected] or Public Relations Thomas Theuringer +49 2103 29 11826 or Robert Reitze +49 2103 29 11676 e-mail: [email protected] [19659008]
[ad_2]
Source link
